Meropenem is widely recognized as one of the most effective antibiotics for the treatment of multidrug-resistant Gram-negative bacterial infections. The high rate of empirical prescribing of this drug in hospitals may contribute to an increase in antimicrobial resistance, making it an important candidate for Drug Utilization Evaluation (DUE).

The primary objective of this study was to assess cases in which Meropenem was prescribed and to evaluate the appropriateness of its use. A retrospective study was conducted to assess the rational use of Meropenem. A total of 50 Meropenem-prescribed cases were evaluated. The findings revealed that 84% of prescriptions were empirical, while 16% were based on specific indications. Culture and sensitivity testing was performed in 82% of cases, whereas no such testing was conducted in 18% of cases.

The maximum prescribed dose among all 50 cases was 1 g, while the minimum dose was 100 mg. The longest duration of therapy was 14 days, and the shortest duration was 2 days. Dose adjustment according to renal status was appropriate in 88% of patients, while 12% received doses that were inappropriate based on their renal function. Of the 50 evaluated cases, 98% of patients responded positively to Meropenem therapy, whereas 2% did not respond to treatment.

These findings indicate that Meropenem was generally prescribed appropriately and demonstrated a high rate of clinical effectiveness. However, the substantial use of empirical therapy highlights the need for continued monitoring, adherence to antimicrobial stewardship principles, and greater reliance on culture and sensitivity testing to minimize the development of antimicrobial resistance.

Keywords: Meropenem, Chemical Structure, Pharmacokinetics and Pharmacodynamics, Side Effects, Clinical Pharmacology.